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require also phosphorylation on a C-terminal serine resi-
due to achieve maximal transactivation potential (David
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Phosphorylation of the conserved tyrosine and serineLos Angeles, California 90095
residues is the only known posttranslational modifica-
tion of STAT proteins. Tyrosine phosphorylation of
STAT1 via the interferon receptor requires the activitySummary
of the Janus Kinase (JAK) family of tyrosine kinases
(Velazquez et al., 1992; Muller et al., 1993; Watling etTranscriptional induction by interferons requires the
al., 1993), whereas serine phosphorylation is thought totyrosine and serine phosphorylation of STAT tran-
be facilitated by members of the MAP kinase familyscription factors. The N-terminal region is highly ho-
(David et al., 1995a). Therefore, it is not surprising thatmologous among the STAT proteins and surrounds
the intracellular domain of the interferon receptors wasa completely conserved arginine residue. Here we
found to provide docking sites for proteins known to bedemonstrate arginine methylation of STAT1 by the
involved in STAT1 phosphorylation events (David et al.,protein arginine methyl-transferase PRMT1 as a novel
1995a, 1995b, 1996a, 1996b). Interestingly, a yeast two-requirement for IFNa/b-induced transcription. Methyl-
hybrid screen recently revealed the interaction of thethioadenosine, a methyl-transferase inhibitor that ac-
protein arginine methyl-transferase PRMT1 with thecumulates in many transformed cells, inhibits STAT1-
IFNAR1 chain of the IFNa/b receptor (Abramovich et al.,mediated IFN responses. This inhibition arises from
1997). PRMT1 was first isolated through its interactionimpaired STAT1-DNA binding due to an increased as-
with BTG1 and TIS21, two genes associated with cellsociation of the STAT inhibitor PIAS1 with phosphory-
quiescence (Lin et al., 1996). Abrogation of PRMT1 ex-lated STAT1 dimers in the absence of arginine methyl-
pression by antisense technology decreased the anti-ation. Thus, arginine methylation of STAT1 is an
viral and antiproliferative abilities of type I interferons,additional posttranslational modification regulating
suggesting a role for PRMT1 in IFNa/b receptor medi-transcription factor function, and alteration of arginine
ated signaling events. In addition, a recent report de-methylation might be responsible for the lack of inter-
scribed the isolation of a novel JAK binding protein 1feron responsiveness observed in many malignancies.
(JBP-1) with arginine methyl-transferase activity (Pol-
lack et al., 1999).Introduction
In the present study, we show that PRMT1 associates
with STAT1 and methylates STAT1 on Arg-31. Muta-STAT (signal transducers and activators of transcription)
tional analysis and the use of the protein methyl-trans-proteins are a family of latent cytoplasmic transcription
ferase inhibitor 59-methyl-thioadenosine (MTA) revealedfactors that are activated by a large number of extracel-
that methylation of STAT1 is required for transcriptionallular signals such as growth factors or cytokines (Schind-
activation. Furthermore, we provide evidence that theler and Darnell, 1995). Seven mammalian STAT family
presence of excess MTA found in certain cancer cellsmembers have been described, and they feature high
is sufficient to inhibit the arginine methylation of STAT1,amino acid homology over several distinct regions.
consequently impairing interferon-mediated gene in-Common to all STAT proteins is an SH2 domain and a
duction and antiproliferation.conserved tyrosine residue whose phosphorylation in
response to receptor activation mediates the homo- or
Resultsheterodimerization of STAT proteins via phosphotyro-
sine/SH2 domain interaction (Heim et al., 1995). Dimer-
PRMT1 Associates with and Methylates STAT1ized STATs can then translocate to the nucleus where
The N termini of the mammalian STAT proteins displaythey bind to conserved enhancer elements and activate
high sequence homology and surround a highly con-transcription of immediate early response genes. In ad-
served arginine residue (Arg-31) found in all seven mam-dition to tyrosine phosphorylation, STATs 1, 3, and 5
malian STATs (Figure 1A). It was previously shown that
mutation of Arg-31 of STAT1, as well as antisense aboli-
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Huntington Avenue, Boston, Massachusetts 02115. reasoned that PRMT1 might exert control over STAT1
Cell
732
Figure 1. STAT1 and PRMT1 Interaction
(A) Alignment of amino acid sequences of the
NH2 termini of STAT proteins Arg-31 of
STAT1 is highly conserved among all seven
STAT proteins.
(B) In vitro methylation of STAT1 on Arg-31.
The indicated amounts of STAT1(NH2)-GST
(lanes 1–3) or STAT1(NH2)-GST (Arg-31!Ala)
(lanes 4 and 5) were subjected to in vitro methyl-
ation assays usingrecombinant PRMT1 (middle
panel) or recombinant PRMT3 (bottom panel).
The input of STAT1-GST proteins was verified
by silver stain (top panel).
(C) STAT1 associates with PRMT1. HeLa cells
were left untreated (lanes 1 and 3) or incu-
bated with IFNa (1000 U/ml). PRMT1 (lanes
1 and 2) and PRMT3 (lanes 3 and 4) were
immunoprecipitated and resolved proteins
were immunoblotted for STAT1.
function by utilizing Arg-31 of STAT1 as a target for of STAT1 and PRMT1. Extracts from untreated or IFNa-
treated HeLa cells were subject to immunoprecipitationmethylation.
To test this hypothesis, we used a GST fusion protein with either anti-PRMT1, anti-PRMT3, or rabbit pre-
immune serum, and resolved immunoprecipitates wereencompassing the first 129 aa of STAT1 for in vitro meth-
ylation assays using recombinant PRMT1 or PRMT3 immunoblotted for the presence of STAT1. As shown in
Figure1C, STAT1 associated with PRMT1 in a ligand-(Figure 1B). Recombinant PRMT1 achieved a robust
methylation of STAT1 (Figure 1B, middle panel, lanes independent manner (lanes 1 and 2). In contrast, STAT1
was not detectable in immunoprecipitates obtained with1–3), whereas the related PRMT3 (Tang et al., 1998)
yielded only a significantly lower methylation of STAT1 PRMT3 serum (lanes 3 and 4) or with preimmune serum
(data not shown). Thus, the selectivity of the in vivo(bottom panel, lanes 1–3). To prove that Arg-31 was
indeed the target for methylation by PRMT1, we intro- association apparently confirms the specificity ob-
served in the in vitro STAT1 arginine methylation assays.duced an Arg-31 to Ala mutation in the STAT1(NH2)-
GST fusion protein to be used in the in vitro methylation
assay. As anticipated, the elimination of Arg-31 resulted STAT1 Is Methylated on Arg-31 In Vivo
Our data clearly established STAT1 as an in vitro sub-in the complete loss of the methylation of the fusion
protein by either PRMT1 or PRMT3 (middle and bottom strate for arginine methylation by PRMT1. In order to
demonstrate that STAT1 is indeed arginine methylatedpanel, lanes 4 and 5). It is important to note that the
STAT1 (NH2/R!A) mutant still contains seven other ar- in vivo, we subjected cell lysates derived from untreated
or IFNa-treated cells to immunoprecipitation usingginine residues. In addition, numerous arginines can be
found in the GST portion of the fusion protein. Neverthe- monoclonal antibodies against dimethylarginine (DMA).
The isolated proteins were then analyzed for the pres-less, only Arg-31 can serve as a target for methylation.
These results not only identify Arg-31 of STAT1 as a key ence of STAT1 by immunoblotting. STAT1 appeared to
be methylated even in untreated cells. However, theresidue for methylation, but also demonstrate substrate
specificity of the two arginine methyl transferases. amount of STAT1 immunoprecipitated with the DMA
antibody appears to increase after stimulation with IFNaPRMT1 has been shown to associate with the IFNa/b
receptor (Abramovich et al., 1997) and our results sug- (Figure 2A, lanes 1 and 2). No STAT1 was detected in
immunoprecipitates obtained with an appropriate iso-gested STAT1 could be a substrate for PRMT1. We
therefore attempted to demonstrate a direct interaction type control antibody (data not shown).
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cells incubated with MTA (Maher, 1993). We therefore
tested whether MTA would inhibit arginine methylation
of STAT1. As anticipated, pretreatment of cells with MTA
prior to IFNa stimulation significantly reduced the
amount of STAT1 that is immunoreactive with DMA anti-
bodies (Figure 2A, lane 3). To demonstrate the specificity
of the antibodies, we performed the immunoprecipita-
tion with the DMA antibodies also in the presence of
either unmethylated or in vitro methylated STAT1(NH2)-
GST. As shown in Figure 2B, only the methylated form
of STAT1(NH2)-GST (lane 2) was able to compete with
STAT1 for binding to the DMA antibody, even though a
substantially larger amount of the unmethylated protein
was added to the lysates (lane 1, lower panel).
In order to determine whether the methylated form of
STAT1 would preferentially localize to the nucleus, we
generated cytoplasmic and nuclear extracts from un-
treated or IFNa-stimulated 2fTGH cells. Analysis of the
amount of STAT1 immunoprecipitated with the DMA
antibodies revealed that approximately 60%–70% of the
methylated STAT1 can be found in the nucleus after
IFNa stimulation (Figure 2C, compare lanes 2 and 4).
Strikingly, only approximately 5%–10% of the total
STAT1 protein can be found in the nuclear extracts of
IFNa2treated cells (lanes 5 and 6). Thus, the stoichiome-
try of methylation is significantly higher in the nuclear
pool of tyrosine-phosphorylated STAT1 when compared
to the cytoplasmic fraction. We next wanted to test
whether tyrosine phosphorylation of STAT1 was a pre-
requisite for its arginine methylation. 293T cells were
transiently transfected with HA-tagged forms of either
wild-type STAT1, STAT1 harboring a nonfunctional SH2
domain, or carrying a mutation in the site of tyrosine
phosphorylation. Probing of the DMA immunoprecipi-
tates with anti-HA antibodies illustrated that tyrosineFigure 2. STAT1 Is Methylated on Arg-31 In Vivo
phosphorylation of STAT1 is not required for its arginine(A) MTA prevents STAT1 arginine methylation. U266 cells were
treated with IFNa without (lane 2) or with (lane 3) pretreatment with methylation (Figure 2D, lanes 5 and 6). Interestingly, a
0.3 mM MTA for 1 hr, and lysates were subject to immunoprecipita- functional SH2 domain appears to be necessary for
tion with DMA antibodies. Resolved proteins were immunoblotted STAT1 to undergo arginine methylation (lanes 3 and 4).
for the presence of STAT1. These results not only demonstrate that tyrosine phos-
(B) Only methylated STAT1(NH2)-GST competes for STAT1 binding
phorylation is not a prerequisite for arginine methylationto DMA antibodies. Cell lysate derived from 2fTGH cells was sub-
of STAT1, but also confirm that the methylation occursjected to immunoprecipitation with mono-/dimethylarginine anti-
bodies in the presence of either STAT1(NH2)-GST (lane 1) or in the cytoplasm since STAT1 (Y701F) is unable to trans-
STAT1(NH2)-GST that had been methylated in vitro by recombinant locate to the nucleus.
PRMT1 (lane 2). Resolved proteins were immunoblotted for the pres- To further verify Arg-31 as the site of STAT1 arginine
ence of STAT1. The amount of STAT1(NH2)-GST added to the cell methylation, we performed mass-spectrometrical analy-
lysate prior to incubation is shown in the lower panel.
sis on STAT1 immunoprecipitated from IFNa-stimulated(C) Cytoplasmic/nuclear distribution of methylated STAT1: 2fTGH
U266 cells. Isolated STAT1 was subject to digestion bycells were treated with 1000 U/ml IFNa for 30 min, and cytoplasmic
(lanes 1 and 2) and nuclear (lanes 3 and 4) extracts were subjected V8 protease, and the masses of the resulting peptide
to immunoprecipitation with mono-/dimethylarginine antibodies. fragments were determined by MALDI-TOF (data not
1% of each extract was also loaded (lanes 5 and 6), and the resulting shown). A fragment with a mass of 1319.74 was identi-
blots probed for STAT1 (cyto 5 cytoplasmic extract; nuc 5 nuclear fied that corresponded to the peptide spanning amino
extract).
acids 30 to 39 (IRQYLAQWLE). Two additional masses(D) Requirements for STAT1 arginine methylation: 293 cells were
at 1333.71 and 1347.68 were detected that conform withtransfected with HA-tagged wild-type STAT1 (lanes 1 and 2),
SH2mut-STAT1 (lanes 3 and 4), or Y701F-STAT1 (lanes 5 and 6). the mono- and dimethylated form of this peptide. These
Whole cell extracts were loaded directly (lower panel), or subjected results clearly demonstrate that STAT1 is arginine meth-
to immunoprecipitation with mono-/dimethylarginine antibodies ylated in vivo, and confirm Arg-31 as the site of this
(upper panel, lanes 1–6) or isotype control (IC) antibodies (lane 7), modification.
and the resulting blots probed with anti-HA antibodies.
Mutation of Arg-31 Alters the Transcriptional
Potential of STAT159-methyl-thioadenosine (MTA) has been reported
as a specific inhibitor of protein methyl transferases Since we had identified Arg-31 as the site of methylation
in vitro and in vivo, we decided to test the effect of(Williams-Ashman et al., 1982), and previous studies
showed that total protein methylation was reduced in mutations in this residue on IFNa-mediated gene tran-
Cell
734
Figure 3. Effects of Arg-31 Mutations on STAT1 Transcriptional
Activity
(A) 293 cells were transiently transfected with IRF-1-luciferase and
GST-fusions of either wild-type STAT1, R31A-STAT1, or R31E-
STAT1. Transcriptional response towards 1000 U/ml IFNa in three
independent experiments is shown.
(B) Lysates from (A) were probed for STAT1 to verify expression
levels of the individual STAT1 mutants.
Figure 4. Effects of MTA on STAT1-Mediated Gene Transcription
scription. We generated STAT1 mutants in which Arg-
(A) MTA inhibits IFNa-mediated ISG54 induction. HeLa cells were31 was replaced with either alanine or glutamic acid,
left untreated (lane 1), or treated with IFNa (1000 U/ml) for 2 hr either
but unfortunately found that these substitutions render in the absence (lane 2) or presence of 0.3 mM (lane 3) MTA. Total
the protein unstable (data not shown). However, we were RNA was isolated, and the amounts of ISG54 (top panel) and GAPDH
(bottom panel) mRNA were determined by RNase protection assay.able to overcome this problem by fusing GST to the N
(B) MTA inhibits IFNa-mediated IRF-1 induction.terminus of the mutant STAT1 proteins. Reporter assays
Same as (A), but a riboprobe corresponding to human IRF-1 wasusing IRF-1-luciferase showed that wild-type GST-
used in the RNase protection assay.STAT1 yielded a 1.4-fold induction in response to IFNa
(C) MTA does not inhibit serum induction of c-fos. Quiescent HeLa
(Figure 3A), which was less when compared to STAT1 cells were stimulated with serum for 20 min in the absence (lane 2)
without GST (data not shown). Nevertheless, mutation or presence of 0.3 mM (lane 3) MTA. Total RNA was isolated, and
the amounts of c-fos (top panel) and GAPDH (bottom panel) mRNAof the positively charged Arg-31 with the hydrophobic
were determined by RNase protection assay.alanine resulted in a significantly increased ability of this
(D) MTA inhibits IFNa-mediated induction of IRF-1-luciferease. 293GST-STAT1 mutant to promote IFNa-mediated tran-
cells were transfected with IRF-1-luciferease and wild-type STAT1,scription. This substitution might mimic the removal of
and the effect of 0.3 mM MTA on the transcriptional response to-
the positive charge of Arg-31 by the methylation reac- wards 1000 U/ml IFNa was analyzed.
tion. An ever stronger increase in the transcriptional
response was observed when Arg-31 was replaced with
the acidic glutamic acid. Equal expression of all GST- feron-inducible ISG54 and IRF-1 genes. As shown in
STAT1 proteins was confirmed by probing the 293T cell Figures 4A and 4B, IFNa stimulation resulted in an in-
lysates with anti-GST antisera (Figure 3B). crease in the levels of ISG54 and IRF-1 mRNA (lanes 1
and 2), genes which are controlled by a STAT1/STAT2
heterodimer or a STAT1 homodimer, respectively. ThisInhibition of Arginine Methyl-Transferase Activity
Decreases STAT1-Mediated Transcription expression was significantly reduced in the presence of
0.3 mM MTA (lanes 3). As it had been previously reportedSince our data supported a role for arginine methylation
in STAT1 function, we decided to investigate the poten- that histones are also subject to methylation (Chen et al.,
1999), we wanted to exclude that reduced methylation oftial effects of the methylation inhibitor MTA on the ca-
pacity of STAT1 to induce gene transcription. Cells were histones was responsible for the observed inhibition of
STAT1-mediated gene transcription by MTA. Strikingly,pretreated with 0.3 mM MTA prior to incubation with
IFNa for an additional 2 hr. Total RNA was isolated and MTA did not effect the serum induction of c-fos, a
STAT1-independent induction (Figure 4C). In addition,hybridized to riboprobes corresponding to the inter-
Arginine Methylation of STAT1
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Figure 5. Effects of MTA on STAT1 Phos-
phorylation, Translocation, and DNA Binding
(A) MTA does not effect STAT1 Tyr-701 or
Ser-727 phosphorylation. U266 cells were
treated with IFNa (1000 U/ml) for 30 min (lane
2), or pretreated with 0.3 mM MTA (lane 3)
for 2.5 hr prior to IFNa treatment. Whole cell
extracts were immunoblotted with STAT1
(phosphoTyr-701) (top panel) or STAT1
(phosphoSer-727) antibody (bottom panel).
(B) MTA does not inhibit STAT1 nuclear trans-
location.
Primary human foreskin fibroblasts were left
untreated (left panel), stimulated with IFNa
(1000 U/ml) for 30 min (middle panel), or pre-
treated with 0.3 mM MTA for 2.5 hr prior to
IFNa stimulation. Subcellular localization of
STAT1 was determined with a monoclonal
antibody against STAT1.
(C) U266 cells were treated with IFNa in the
absence (lane 2) or presence (lane 3) of 0.3
mM MTA, and EMSAs were performed using
the GRR element as a probe.
(D) U266 cells were treated for the indicated
times with IFNa in the absence (lanes 2 and
3) or presence (lanes 4 and 5) of 0.3 mM MTA.
STAT1 was immunoprecipitated, and isolated
proteins were probed for the presence of
PIAS1. The blot was subsequently reprobed
for STAT1 to ensure equal protein loading.
MTA was also able to exert its inhibitory effect when STAT1-regulated transcription relies on binding to de-
fined response elements within the promoters of STAT1-transcription was analyzed by means of an IRF-1-lucifer-
ase reporter assay (Figure 4D). regulated genes. We therefore analyzed whether MTA
treatment would alter the DNA binding of STAT1 after
IFNa stimulation. EMSAs using the STAT1-specific GRRArginine Methylation Alters STAT1 DNA Binding
by Regulating PIAS Association element as a probe revealed that MTA pretreatment
reduced the ability of tyrosine phosphorylated STAT1Since tyrosine and serine phosphorylation of STAT1 are
absolute prerequisites for its transactivating capabilities to bind DNA (Figure 5C, lanes 2 and 3). To ensure that
MTA did not prohibit STAT1 DNA interactions by direct(Shuai et al., 1993; Wen et al., 1995), we stimulated cells
for 30 min with IFNa without or with preincubation with interference with the in vitro binding conditions, we
added MTA directly to cell lysates from cells treated0.3 mM MTA, and immunoblotted the resulting cell ly-
sates with antibodies specific for STAT1 (phosphoTyr- with IFN only. Under those circumstances, MTA had no
effect on STAT1 DNA binding (data not shown). The701) (Figure 5A, upper panel) and STAT1 (phosphoSer-
727) (lower panel). Our results illustrate that there is no effect of MTA was preserved in the presence of the
protein synthesis inhibitor cycloheximide (data notobvious defect in the IFNa-induced tyrosine phosphory-
lation of STAT1 due to pretreatment with MTA. Similarly, shown), excluding the possibility of induction of an inhib-
itor by the MTA pretreatment.phosphorylation of Ser-727, though constitutive, was
not affected by the presence of MTA. The reduction in STAT DNA binding we observed after
MTA treatment is reminiscent of the actions of membersTo ensure that MTA did not affect the ability of STAT1
to translocate to the nucleus, we determined the subcel- of the protein inhibitor of activated STATs (PIAS) family
(Chung et al., 1997; Liu et al., 1998). Addition of recombi-lular localization of STAT1 by immunohistochemistry us-
ing a monoclonal STAT1 antibody (Figure 5B). Concomi- nant PIAS1 protein to cell extracts derived from IFN-
treated cells interfered with the DNA binding of STAT1tant with the intact phosphorylation of STAT1, we found
that the nuclear translocation of STAT1 was not affected (Liu et al., 1998). PIAS1 was found to specifically associ-
ate with STAT1, but not with other STAT proteins. Fur-by the presence of MTA.
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thermore, a recent report demonstrated that the interac- cell lysates resulted in a pronounced arginine methyla-
tion of STAT1-GST, no methylation could be detectedtion of PIAS1 with STAT1 occurs at the N terminus where
Arg-31 is located (Liao et al., 2000). Therefore, we inves- when A549-MTAP(2/2) cell lysate was used (Figure 6B).
Interestingly, Western blotting of the same lysates indi-tigated if the inhibition of STAT1 DNA binding in the
presence of MTA was due to an increase in PIAS1 asso- cated the A549-MTAP(2/2) cells expressed even higher
levels of PRMT1 than their reconstituted counterparts,ciation. STAT1 immunoprecipitates obtained from cells
treated with IFNa in the absence or presence of MTA suggesting a compensatory reaction of the cells in re-
sponse to the inhibition of endogenous protein argininewere analyzed for the presence of PIAS1 protein.
Whereas PIAS1 was essentially undetectable in STAT1 methylation reactions by accumulated MTA (Figure 6B,
lower panel).immunoprecipitates from IFNa-stimulated cells (Figure
5D, lanes 2 and 3), a dramatic increase in PIAS1 binding To further assure that the observed differences in the
in vitro methylation reactions were not due to a potentialto STAT1 was observed when MTA was present during
the stimulation (lanes 4 and 5). No PIAS1 protein was defect in the activity of endogenous PRMT1, we re-
peated the experiments with recombinant PRMT1. Thedetected when preimmune serum was used for immuno-
precipitation (data not shown). Increased PIAS1 associ- addition of increasing amounts of A549-MTAP(1/1) ly-
sate had no detectable effect on STAT1(NH2)-GSTation was not due to upregulation of PIAS1 protein (data
not shown). This result suggests that inhibition of STAT1 methylation (Figure 6C, lanes 2, 4, and 6). In contrast,
the presence of an increasing amount of lysates derivedarginine methylation by MTA facilitates an interaction
with the STAT1 inhibitor PIAS1. from A549-MTAP(2/2) cells resulted in a drastic, dose-
dependent inhibition of STAT1(NH2)-GST methylation
(lanes 1, 3, and 5). To verify that the inhibitory activityAccumulated MTA in Transformed Cells Inhibits
present in the lysate derived from A549-MTAP(2/2)STAT1 Methylation
cells was indeed MTA, we incubated these cell lysatesMTA is not only a pharmacological agent used to inhibit
without and with recombinant, purified MTAP prior toarginine methylation in vitro, but is actually generated
addition of the lysate to the in vitro methylation reac-in vivo as a metabolic intermediate in the conversion of
tions. As shown in Figure 6D, preincubation of the cellputrescine to spermidine and of spermidine to spermine
lysate with rMTAP reduced the inhibitory activity of the(Williams-Ashman et al., 1982). Methyl-thioadenosine
A549-MTAP(2/2) cell lysates.phosphorylase (MTAP), an enzyme in the salvage path-
These results demonstrate that the absence of MTAPway for adenine nucleotide and in methionine biosynthe-
and consequential accumulation of MTA do not inhibitsis, efficiently catalyses the breakdown of cellular MTA
STAT1 Tyr-701 or Ser-727 phosphorylation, but have ato almost undetectable levels (Kamatani et al., 1981).
dramatic effect on the in vitro methylation of STAT1Due to their genomic proximity, MTAP is often found
(NH2)-GST.homozygously codeleted with the p16 tumor suppressor
gene locus in a large number of cancers (Nobori et al.,
1996). Since MTAP is the sole enzyme responsible for Characterization of the Interferon Response
in A549-MTAP(2/2) CellsMTA cleavage, we reasoned that MTAP deficiency could
result in sufficient accumulation of MTA to cause an Our earlier biochemical analysis using exogenous MTA
suggested a role for arginine methylation in STAT1-inhibition of endogenous protein methyl transferases. To
test this hypothesis, we decided to analyze the effects of mediated transcription. Therefore, the possibility of a defi-
ciency in the expression of STAT1-driven genes in A549-interferon on the MTAP-deficient human lung carcinoma
cells A549-MTAP(2/2), and their MTAP-reconstituted MTAP(2/2) cells was investigated. A549-MTAP(2/2) or
A549-MTAP(1/1) cells were treated with IFNb, and totalcounterpart A549-MTAP(1/1) (Nobori et al., 1996).
First, we wanted to verify that the interferon-induced RNA was analyzed for the presence of IRF-1 and GAPDH
mRNA. Only RNA isolated from IFNb-stimulated A549-STAT1 phosphorylation pathway was intact. We there-
fore treated A549-MTAP(2/2) or A549-MTAP(1/1) cells MTAP(1/1), but not from A549-MTAP(2/2) cells, con-
tained detectable amounts of IRF-1 mRNA (Figure 7A,with IFNa or IFNb for 30 min, and analyzed for the levels
of STAT1 phosphoTyr-701 or STAT1 phosphoSer-727 compare lanes 2 and 4). In conformity with the mRNA
levels, IRF-1 protein was only found induced in A549-by Western blot (Figure 6A). As anticipated from the
experiments applying exogenous MTA, we detected no MTAP(1/1) (Figure 7B, lanes 6 to 10), but not in A549-
MTAP(2/2) cells (lanes 1 to 5) following stimulation bydifferences in STAT1 Tyr-701 or Ser-727 phosphoryla-
tion between the A549-MTAP(2/2) and A549-MTAP(1/1) IFNb.
The obvious defect in the expression of an interferon-cells. Similarly, immunofluorescence of A549-MTAP(2/2)
and A549-MTAP(1/1) cells displayed equal nuclear ac- induced gene that contributes significantly to the anti-
proliferative function of this cytokine led us to considercumulation of STAT1 in response to IFNa and IFNb stim-
ulation (data not shown). the possibility that A549-MTAP(2/2) cells may display
defects in the biological response to IFN. To test thisAs we hypothesized that the A549-MTAP(2/2) cells
may accumulate MTA, we tested if the cytosolic MTA hypothesis, we employed proliferation assays on A549-
MTAP(2/2) and A549-MTAP(1/1) cells. Although bothconcentration in A549-MTAP(2/2) cells was indeed ad-
equate to inhibit in vitro methylation reactions. We first cell lines exhibited the same growth rate when left un-
treated, the A549-MTAP(2/2) cells displayed a markeddetermined the activity of endogenous PRMT1 in A549-
MTAP(2/2) or A549-MTAP(1/1) cell lysates by in vitro defect with regards to their antiproliferative response
toward Type I IFNs. Compared to the A549-MTAP(1/1)methylation assays using STAT1(NH2)-GST as a sub-
strate. Whereas the addition of lysate from MTAP(1/1) cells, A549-MTAP(2/2) cells were significantly less af-
Arginine Methylation of STAT1
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Figure 6. Effect of MTAP Deletion on STAT1
Function
(A) Intact STAT1 (Tyr-701) or (Ser-727) phos-
phorylation in MTAP-deficient cells. A549-
MTAP(2/2) or A549-MTAP(1/1) cells were
left untreated (lanes 1 and 4), or treated for
30 min with 1000 U/ml IFNa (lanes 2 and 5)
or IFNb (lanes 3 and 6). Equal amounts of pro-
tein were immunoblotted with either STAT1
(phosphoTyr-701) (top panel) or STAT1 (phos-
phoSer-727) antibody (bottom panel).
(B) Reduced STAT1 arginine methylation in
A549-MTAP(2/2) cell lysates.
Lysates (30 ml) of A549-MTAP(2/2) (lane 1)
or A549-MTAP(1/1) (lane 2) cells were added
to an in vitro methylation reaction using GST-
STAT1 as substrate (top panel). Lysates from
both cell lines were resolved on SDS-PAGE
and immunoblotted for endogenous PRMT1
(bottom panel).
(C) A549-MTAP(2/2) lysates inhibit STAT1
methylation by recombinant PRMT1.
10 ml (lanes 1 and 2), 20 ml (lanes 3 and 4), or
30 ml (lanes 5 and 6) total cell lysate derived
from A549-MTAP(2/2) or A549-MTAP(1/1)
were added to an in vitro methylation reaction
utilizing recombinant PRMT1 and GST-STAT1
as a substrate.
(D) MTAP treatment of A549 cell lysate re-
duces its inhibitory activity.
A549 cell lysate was incubated without (lanes
1, 3, and 5) or with recombinant MTAP (lanes
2, 4, and 6) for 30 min at 308C, and the indi-
cated amount of the lysates was added to
the in vitro methylation reactions as in (C).
fected in their growth by IFNa or IFNb at any of the demonstrated that GST-STAT1(NH2) was efficiently
methylated on Arg-31, particularly in the presence ofconcentrations tested (Figure 6B).
These observations strongly support our model that recombinant PRMT1. Intriguingly, the sequence sur-
rounding Arg-31 bears little resemblance to the pro-MTAP deficiency will lead to a sufficiently high accumu-
lation of MTA to result in inhibition of STAT1 methylation posed glycine-rich consensus sequence observed in
other arginine-methylated proteins (Clarke, 1993; Garyand cause diminution of the biological responses to
IFNs. and Clarke, 1998). Although the GST-STAT1(NH2) con-
struct contained 20 additional arginine residues, muta-
tion of the Arg-31 to alanine completely abolished meth-Discussion
ylation. This was quite surprising since in an in vitro
system utilizing high levels of recombinant enzyme, oneInvestigations into STAT1 regulation have focused heav-
ily on posttranslational amino acid modification by phos- might expect less specificity than in vivo. The specificity
of the methylation reaction was also illustrated by thephorylation. In particular, phosphorylation of Tyr-701
has been found to be essential for dimerization, nuclear fact that PRMT1 was significantly more efficient in cata-
lyzing STAT1 methylation than PRMT3. Indeed, coimmu-translocation, and DNA binding of STAT proteins
(Schindler and Darnell, 1995). In addition, concomitant noprecipitation studies detected an interaction between
STAT1 and PRMT1, but not PRMT3. These results dem-phosphorylation of Ser-727 results in a significant in-
crease in the transactivating potential of STAT1 (Wen onstrated that Arg-31 of STAT1 is an efficient substrate
for methylation, and PRMT1 is capable of mediating thiset al., 1995). It is also thought that the N terminus of
STAT1 mediates interactions with other regulatory pro- reaction. Immunoprecipitations of STAT1 with dimethyl
arginine antibodies, as well as mass-spectrometric anal-teins that exert a modifying effect on STAT phosphoryla-
tion. As such, the deletion of the first 62 amino acids of ysis, confirmed that STAT1 is indeed methylated on Arg-
31 in vivo. Through the use of cytoplasmic and nuclearSTAT1 results in delayed inactivation and an alteration
in the antiproliferative response toward interferon (Shuai extracts, as well as several STAT1 mutants, we were
able to show that methylation of STAT1 occurs in theet al., 1996).
Alignment of N termini of the seven mammalian STATs cytoplasm and requires a functional STAT1-SH2 do-
main, but is independent of STAT1 tyrosine phosphory-reveals a region of high homology and an invariant argi-
nine at position 31, suggesting functional importance of lation. It is interesting to note that only 5–10% of the
total cellular STAT1 was found in the nucleus after IFNathis residue. Using an in vitro methylation assay, we
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by mutational analysis. Methylation of this positively
charged amino acid results in the elimination of the
positive charge and an increase in hydrophobicity. In-
deed, replacement of arginine 31 with an uncharged
hydrophobic alanine residue results in increased tran-
scriptional activity. Moreover, substitution of arginine
with the acidic and negatively charged glutamic acid
further increased the ability of STAT1 to promote tran-
scription.
Although inhibition of STAT1 arginine methylation by
MTA had no effect on its tyrosine phosphorylation,
STAT1 interaction with DNA was significantly impaired in
the absence of STAT1 methylation. Loss of IFN-induced
STAT1 DNA binding is reminiscent of the action of the
PIAS family of STAT inhibitors whose presence has been
demonstrated to inhibit STAT DNA binding (Chung et
al., 1997; Liu et al., 1998). Indeed, inhibition of arginine
methylation by MTA allows for an association between
STAT1 and the PIAS1 protein that inhibits STAT DNA
binding and induced transcription.
MTA is the substrate of methyl-thioadenosine phos-
phorylase (MTAP), a catabolic enzyme in the purine sal-
vage pathway. MTAP has been the focus of several
cancer-related studies as its gene is near the p16 locus
and is codeleted in at least 85% of p162/2 human
cancers (Fitchen et al., 1986; Smaaland et al., 1987;
Carson et al., 1988; Traweek et al., 1988; Nobori et al.,
1991, 1993; Della Ragione et al., 1992, 1993, 1995; Zhang
et al., 1996). As cellular MTA levels are regulated by
MTAP degradation, we investigated the possibility that
MTAP(2/2) cells could accumulate a sufficient concen-Figure 7. Reduced IFN Responsiveness in A549-MTAP(2/2) Cells
tration of endogenous MTA to inhibit cellular protein(A) A549-MTAP(2/2) lack IFN-induced IRF-1 mRNA. A549-
arginine methylation activity. When added to an in vitroMTAP(2/2) (lanes 1 and 2) or A549-MTAP(1/1) cells (lanes 3 and
methylation assay, A549-MTAP(2/2) cell lysates com-4) were left untreated (lanes 1 and 3), or treated with 1000 U/ml
IFNb (lanes 2 and 4) for the indicated times. Total RNA was isolated, pletely inhibited STAT1 arginine methylation by endoge-
and RNase protection assays were performed using IRF-1 and nous or recombinant PRMT1 while A549-MTAP(1/1)
GAPDH as probes. lysates did not alter STAT1 methylation. Moreover, the
(B) A549-MTAP(2/2) lack IFN-induced IRF-1 expression. A549-
inhibitory capacity of A549-MTAP(2/2) lysates was re-MTAP(2/2) (lanes 1–5) or A549-MTAP(1/1) cells (lanes 6–10) were
duced following pretreatment with purified MTAP. Weleft untreated (lanes 1 and 6), or treated with 1000 U/ml IFNb (lanes
conclude that MTA concentrations in MTAP(2/2) cells2–5 and 7–10) for the indicated times. Lysates were resolved by
SDS-PAGE and immunoblotted for IRF-1. are sufficient to inhibit protein arginine methylation. In-
(C) Reduced antiproliferative effect of IFNa/b in A549-MTAP(2/2) terestingly, the level of endogenous PRMT1 appears
cells. elevated in MTAP(2/2) cells and may be a compensa-
A549-MTAP(2/2) or A549-MTAP(1/1) cells were cultured in the tory mechanism for the inhibition of arginine methylation
presence of 100, 1000, or 10,000 U/ml of IFNa or IFNb. A nonradioac-
caused by excess MTA.tive cell proliferation assay was performed four days after plating,
Examination of the interferon-induced expression ofand a representative of three identical experiments is shown above.
IRF-1 in MTAP(2/2) and MTAP(1/1) cells at the RNA
and protein level demonstrated a substantial induction
stimulation, indicating that only a small fraction of STAT1 of IRF-1 in MTAP(1/1) cells that is starkly absent in
undergoes ligand-induced tyrosine phosphorylation and MTAP(2/2) cells. It thus appears that the lack of arginine
nuclear translocation. Nevertheless, more than 60% of methylation of STAT1 in MTAP(2/2) cells produces a
the methylated form of STAT1 was found in the nucleus, significant decrease in STAT1-induced transcription of
suggesting that the stoichiometry of methylation is sig- IRF-1 and possibly other tumor suppressor genes. This
nificantly higher in the nuclear pool of tyrosine phos- difference in IRF-1 induction parallels a greater antipro-
phorylated STAT1. liferative effect of IFNa/b in MTAP(1/1) cells compared
To investigate the biological importance of arginine to MTAP(2/2) cells. Thus, the inhibition of STAT1 argi-
methylation in STAT1-mediated gene induction, we uti- nine methylation by increased amounts of intracellular
lized the methyl-transferase inhibitor MTA, which com- MTA seems to inhibit the biological effects of interferon.
pletely abrogated IFNa/b-induced gene transcription The role of arginine methylation in signal transduction
without affecting STAT1 tyrosine or serine phosphoryla- events has not been widely explored. Levels of cellular
tion. Arginine methylation of STAT1 is found at substan- arginine methylation have been shown to rise following
tial levels in unstimulated cells, but is nevertheless sen- NGF stimulation of PC12 cells (Cimato et al., 1997) and
sitive to inhibition by MTA. The importance of Arg-31 in lipopolysaccharide treatment of B cells (Law et al.,
1992). Defined substrates for arginine methylation in-IFNa-mediated gene transcription is further illustrated
Arginine Methylation of STAT1
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Cell Extracts and Electrophoretic Mobility Shiftclude FGF (Burgess et al., 1991; Pintucci et al., 1996),
Assay (EMSA)nucleolin (Najbauer et al., 1993), and fibrillarin (Najbauer
To generate whole cell lysates, cells were lysed on the plates withet al., 1993), as well as hnRNP A1 (Shen et al., 1998)
lysis buffer (1 ml) containing 20 mM Hepes pH 7.4, 1% TX-100, 100
and hnRNP A2 (Nichols et al., 2000) where arginine meth- mM NaCl, 50 mM NaF, 10 mM b-glycerophosphate, 1 mM sodium-
ylation is implicated in hnRNP nuclear localization. Addi- vanadate, and 1 mM PMSF. For coimmunoprecipitation experi-
ments, cells were lysed in buffer containing 100 mM NaCl, 50 mMtionally, a recent study reported the isolation of a coacti-
TRIS pH 7.5, 1 mM EDTA, 0.1% TX-100, 10 mM NaF, 1 mM PMSF,vator–associated arginine methyl transferase 1 (CARM1)
and 1 mM vanadate. Lysates were centrifuged at 13,000 rpm for 5whose activity enhanced the transcriptional activity of
min and protein concentration was determined by Lowry (BioRadcertain nuclear hormone receptors, but only when ex-
Protein Assay). Cytoplasmic/nuclear extracts were prepared by
pressed with members of the p160 family of coactivators douncing cells in Buffer A (20 mM HEPES pH 7.9, 10 mM KCl, 1 mM
(Chen et al., 1999). Interestingly, arginine methylation MgCl2, 10% Glycerol, 0.1% NP40) and sedimentation of nuclei by
centrifugation at 1000 rpm for 5 min. Supernatant (5cytoplasmicwithin a proline-rich region in Sam68, a proposed adap-
extract) was removed, and nuclei were extracted with Buffer A con-tor for src kinases, was shown to prohibit interaction
taining 300 mM NaCl (5nuclear extract). EMSAs were performedwith SH3 domains while maintaining the ability of Sam68
using whole cell extracts and an end-labeled oligonucleotide corre-to interact with WW domains (Bedford et al., 2000). Thus,
sponding to the GRR sequence of the FcgRI gene (Wilson and Fin-
arginine methylation of Sam68 modulates its interac- bloom, 1992).
tions with SH3- and WW- containing proteins. We envi-
sion a similar scheme for STAT-PIAS interactions where Immunoprecipitation and Immunoblotting
Cell lysates were precleared with Protein G-Sepharose for 30 min,arginine methylation obstructs the interaction of STAT1
and incubated with preimmune sera or antisera to PRMT1, PRMT3,with its inhibitor PIAS1. Indeed, the amino-terminal do-
or STAT1 and protein G-Sepharose overnight at 48C. After SDS-main of STAT1 (aa 1–191) where arginine 31 is located
PAGE and transfer onto PVDF membrane, proteins were detectedis necessary for association with PIAS1. It is interesting
with anti-STAT1 (Transduction Labs), anti-phosphoSTAT1 Y701
to note that similar regions of STAT1 are required for (New England Biolabs), anti-phosphoSTAT1 Ser-727 (Upstate Bio-
PIAS1 interaction and for tyrosine dephosphorylation; technology, Inc.), anti-IRF-1, or anti-PIAS1 antibodies (Santa Cruz).
For dimethyl-arginine immunoprecipitations, cell lysates were incu-it is therefore possible that these events occur in a coor-
bated with monoclonal mono/dimethyl-arginine or dimethyl-argininedinated manner.
antibodies (Abcam) or an isotype control antibody overnight at 48C.In summary, arginine methylation is an additional
For antigen-block experiments, the cell lysate was divided in half,STAT1 modification, one that appears deficient in
and unmethylated or in vitro methylated STAT1(NH2)-GST was
MTAP(2/2) cells due to accumulation of a biological added prior to the dimethyl-arginine antibodies. Immunoreactive
inhibitor of arginine methyl transferases. Since MTAP is proteins were resolved by SDS-PAGE, and blots were immunoblot-
ted with monoclonal STAT1 antibodies. All blots were developedfrequently deleted in cancers, its presence might prove
with HRP-conjugated secondary antibodies and ECL (Amersham).useful as a prognostic marker for interferon therapy.
Proliferation AssaysExperimental Procedures
A549- and A549-MTAP reconstituted cells were seeded at 100 cells/
well with indicated amounts of IFNa or IFNb or left untreated forCell Culture
three days before analysis with a Non-radioactive Cell ProliferationPrimary human fibroblasts, HeLa, HEK293, and A549 cells were
Assay (Promega). Assays were performed according to manufactur-maintained in DMEM, and U266 cells were cultured in RPMI1640.
er’s instructions.All media was supplemented with penicillin and streptomycin, and
10% fetal bovine serum (10% horse serum for A549 cells).
Immunofluorescence
Cells were seeded onto coverslips and incubated overnight at 378C
Interferons and Reagents in DMEM containing 10% FBS. After treatment, coverslips were
IFNa and IFNb were generous gifts from Hoffman LaRoche and rinsed with PBS followed by one wash with PIPES buffer. Cells were
Biogen Inc., respectively. 3H-S-Adenosyl-methionine was obtained fixed in methanol at room temperature and nuclei permeabilized
from ICN Pharmaceuticals. 59-methyl-thioadenosine (MTA) was pur- with 0.5% Nonidet P-40/PB. Coverslips were washed three times
chased from Sigma and dissolved in culture medium. with PBS, blocked with 10% goat serum, and incubated with anti-
STAT1 antibodies (Transduction Laboratory). Cells were rinsed four
Plasmids times with PBS prior to incubation with Cy3-conjugated secondary
GST-STAT1 and GST-STAT1(R31A) have been described previously. antibody. After washing, coverslips were mounted onto glass slides
GST-STAT1(R31E) was generated by site-directed mutagenesis us- in 50% glycerol/PBS.
ing QuickChange (Stratagene). Plasmids encoding GST fusion pro-
teins of STAT1 amino acids 1–129, and the same region with the RNase Protection Assays
Arg-31!Ala mutant, were generated by excision of a BamHI/SspI Total RNA was isolated using TRIzol Reagent. 32P-labeled ribo-
fragment from pEBG GST-STAT1 and pEBG GST-STAT1 (Arg !Ala), probes were generated by in vitro transcription using T3, T7, or SP6
respectively, and ligation into the BamHI/SmaI sites of pGEX-KG RNA polymerase (Promega). Labeled riboprobe and 10 mg of RNA
(Pharmacia), which had been modified to accept the BamHI/SmaI were incubated in hybridization buffer (4:1 formamide and 53 stock;
insert. GST-PRMT1 and GST-PRMT3 were previously described (Lin 53 stock was 200 mM PIPES, pH 6.4, 2 M NaCl, 5 mM EDTA)
et al., 1996). overnight at 568C prior to digestion with T1 RNase. Protected frag-
ments were separated by electrophoresis on a 4.5% polyacrylamide/
urea gel.In Vitro Methylation Reactions
Two mg GST-PRMT1 or GST-PRMT3 were incubated with 10–15 mg
of (GST-STAT1–129) or (GST-STAT1–129 Arg-31!Ala) and 2 ml of Luciferase Assays
Cells were transiently transfected with either ISRE or IRF-1 firefly[3H] Ado-Met (NEN Life Science, 0.55 mCi/ml) raised to a final volume
of 80 ml with PBS and incubated for 90 min at 378C. Reactions were luciferase reporter plasmids and STAT1 constructs, as indicated in
the figure legends, using Superfect (Qiagen). Renilla luciferase underterminated by the addition of SDS-loading buffer. A549 and A549-
MTAP reconstituted cell lysates were obtained by scraping cells the control of the thymidine kinase promoter was cotransfected
as an internal standard. Firefly and renilla luciferase activity wereinto PBS followed by sonication and centrifugation.
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determined using Promega’s Dual Luciferase Kit according to the quired for IFNa/b-induced gene expression. J. Biol. Chem. 271,
15862–15865.manufacturer’s instructions, and firefly luciferase activity was nor-
malized to renilla luciferase activity. Della Ragione, F., Oliva, A., Palumbo, R., Russo, G.L., Gragnaniello,
V., and Zappia, V. (1992). Deficiency of 59-deoxy-59-methylthioade-
Mass-Spectrometric Analysis nosine phosphorylase activity in malignancy. Absence of the protein
U266 cells were treated with IFNa for 30 min, STAT1 was immuno- in human enzyme-deficient cell lines. Biochem. J. 281, 533–538.
precipitated from the lysates and resolved on 7.5% SDS-PAGE. Della Ragione, F., Oliva, A., Palumbo, R., Russo, G.L., and Zappia,
The excised gel band was subject to in-gel digestion with Glu-C V. (1993). Enzyme deficiency and tumor suppressor genes: absence
(Promega). Extracted peptides were purified using a reversed-phase of 59-deoxy-59-methylthioadenosine phosphorylase in human tu-
microcolumn (C18 Zip-tip, Millipore) and analyzed on a MALDI-TOF mors. Adv. Exp. Med. Biol. 348, 31–43.
mass spectrometer (PE Voyager DE-STR) using a-cyano-4-hydro-
Della Ragione, F., Russo, G., Oliva, A., Mastropietro, S., Mancini,xycinnamic acid as matrix.
A., Borrelli, A., Casero, R.A., Iolascon, A., and Zappia, V. (1995).
59-Deoxy-59-methylthioadenosine phosphorylase and p16INK4 defi-
Acknowledgments ciency in multiple tumor cell lines. Oncogene 10, 827–833.
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